ALTERITY THERAPEUTICS LTD (ATHE) entered into an Underwriting Agreement with MST Financial Services Pty Ltd, which has agreed to underwrite the exercise of up to 8,400,000 unexercised ATHO listed options ahead of their expiry. These Underwritten Options are expected to raise approximately A$4.2 million before costs.
There are currently 15,918,235 ATHO options on issue, exercisable at A$0.50 and expiring at 5:00pm (AEST) on 31 August 2026. Subject to completion of the underwriting and depending on how many options are exercised by holders, Alterity will issue between 8,400,000 and 15,918,235 new shares and raise approximately A$4.2–7.96 million before costs.
The underwriter will receive a 7% fee on gross proceeds from underwritten option exercises and may allocate Underwritten Shares to sub-underwriters that are sophisticated and professional investors. Proceeds are expected to support late-stage clinical development of ATH434 in Multiple System Atrophy and general working capital. The agreement includes customary conditions and termination events and may be terminated by either party in specified circumstances.
ALTERITY THERAPEUTICS LTD (ATHE) reports that it has filed its Annual Report on Form 20-F, including audited consolidated financial statements for the year ended June 30, 2026, with the U.S. Securities and Exchange Commission. The report and related XBRL interactive data are available on the company’s website, and shareholders can request a hard copy free of charge.
Alterity describes itself as a clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative diseases, with a focus on Multiple System Atrophy and related Parkinsonian disorders. The company is preparing to initiate a Phase 3 pivotal trial of its lead asset ATH434, following clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data from an open-label Phase 2 trial in advanced MSA.
ALTERITY THERAPEUTICS LIMITED (ATHE) filed an annual report describing its development-stage neurology business focused on ATH434 for multiple system atrophy (MSA) and other Parkinsonian disorders. ATH434 is the lead and highly concentrated asset; Alterity reported positive FDA feedback and End‑of‑Phase 2 alignment on key elements of a registrational Phase 3 program.
The company’s ordinary shares trade primarily on the ASX and its American Depositary Shares, each representing 12 ordinary shares, trade on the Nasdaq Capital Market under “ATHE.” Ordinary shares outstanding were 217,508,862 as of June 30, 2026. Financial statements are prepared in Australian dollars under IFRS.
Alterity reported operating losses of A$23.4 million in fiscal 2026 and A$12.1 million in 2025, with operating cash outflows of A$22.5 million and A$11.5 million, and expects continued losses and substantial additional capital needs. The report highlights extensive clinical, regulatory, manufacturing, data‑privacy, intellectual property, healthcare policy, currency, listing‑compliance, geopolitical and Australian‑jurisdiction risks, including PFIC tax risk for certain U.S. holders and potential dilution from future financings.
Alterity Therapeutics Limited (ATHE) files a corporate governance statement outlining how its practices align with the ASX Corporate Governance Council’s 4th Edition Principles. The company reports broad compliance across eight governance principles, using a formal Corporate Governance Plan and multiple board charters and policies available on its website.
The Board has 5 directors, with 3 independent (including Chair Julian Babarczy), and operates Audit and Remuneration Committees since November 2025. Diversity disclosures show females comprise 20% of the Board, 0% of executive officers, 46% of senior management and 54.5% of the total workforce. The company partially complies with recommendations on gender diversity targets and having a dedicated Nomination Committee, citing its small size and having the full Board perform nomination and some risk-oversight functions. The statement also confirms annual risk framework reviews, senior executive performance evaluations, and the use of policies covering code of conduct, whistleblowing, anti-bribery and continuous disclosure.
Alterity Therapeutics Limited (ATHE) has furnished an Appendix 4G and related corporate governance disclosures for the financial year ended 30 June 2026. The company states that its corporate governance statement for this period is available on its website at https://alteritytx.com/governance/ and that it is accurate and up to date as at 28 August 2026, having been approved by the board.
The Appendix 4G maps how Alterity applies the ASX Corporate Governance Council’s Principles and Recommendations, including disclosures on board charter and responsibilities, diversity policy and gender reporting, performance evaluations of the board and senior executives, board skills matrix, independence and tenure of directors, risk oversight, audit and remuneration committee charters, whistleblower and anti-bribery policies, and environmental and social risk disclosures. Many detailed governance items are cross-referenced to the 2026 Annual Report and governance materials on the company’s website.
Alterity Therapeutics Limited reports that the U.S. Patent and Trademark Office has granted a new composition of matter patent for ATH434, its lead clinical asset for Multiple System Atrophy (MSA), Parkinson’s disease and related disorders. The patent covers a crystalline form of ATH434 mesylate and associated treatment methods and extends protection to at least 2045, adding a key layer of intellectual property as ATH434 moves toward planned Phase 3 development in MSA by year-end 2026. The company notes that this protection supports potential commercial value, partnership opportunities and expansion of ATH434 into Parkinson’s disease and other neurodegenerative indications, alongside existing Fast Track and Orphan Drug Designations for MSA.